Is CytomX Therapeutics Inc (CTMX) overvalued? · rev $138.1M
CytomX Therapeutics Inc (CTMX) is a biotechnology company listed on US.
This page asks whether CytomX Therapeutics Inc (CTMX) looks expensive on cached numbers — not a short thesis.
Latest reported CTMX revenue for 2024-12-31 was $138.1M. Net income was $31.9M. Revenue was up 36.4% from 2023-12-31 to 2024-12-31. CTMX currently screens at market cap $653.1M.
CTMX currently screens at market cap $653.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CTMX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CTMX stock page for the full model, not this heading.
Not investment advice.